[Adjuvant immunotherapy for carcinoma of uterine cervix with PSK].
The subjects in this study were 123 cases of patients with carcinoma of uterine cervix who underwent surgery and postoperative irradiation or only irradiation combining with PSK as adjuvant immunotherapy. The changes in the immunological status of the patients were studied using various types of immunological parameters, and the two-year survival rate was also followed up. DNCB and PHA skin reaction showed no particular differences between the control and the PSK combination group, but the blast-formation of lymphocyte by PHA tended to show a rapid recovery from the reduction of the postirradiation in the PSK combination group. From the observations of changes in the peripheral T gamma and T cells, the combination use of PSK tended to cause a decrease in T gamma and an increase in T mu cells, but the both cell numbers were fallen in the normal range. The two-year survival rate of stage III patients was somewhat higher in the PSK combination group than in the control group; however, the difference between both groups was not statistically significant.
D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D010835:Phytohemagglutinins / Q000494:pharmacology; D011509:Proteoglycans / Q000627:therapeutic use*; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000628:therapy*
D010835:Phytohemagglutinins; D011509:Proteoglycans; C010770:polysaccharide-K